Compare CNM & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNM | PODD |
|---|---|---|
| Founded | 1996 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Durable Goods | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 10.3B |
| IPO Year | 2021 | 2007 |
| Metric | CNM | PODD |
|---|---|---|
| Price | $48.26 | $152.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 21 |
| Target Price | $61.55 | ★ $341.48 |
| AVG Volume (30 Days) | ★ 2.8M | 1.5M |
| Earning Date | 06-09-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.45 | N/A |
| EPS | 0.57 | ★ 1.30 |
| Revenue | ★ $7,647,000,000.00 | $2,708,100,000.00 |
| Revenue This Year | $4.89 | $24.55 |
| Revenue Next Year | $4.21 | $19.18 |
| P/E Ratio | ★ $84.14 | $121.33 |
| Revenue Growth | 2.77 | ★ 30.73 |
| 52 Week Low | $43.96 | $138.79 |
| 52 Week High | $67.18 | $354.88 |
| Indicator | CNM | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 47.47 | 50.10 |
| Support Level | $44.79 | $141.67 |
| Resistance Level | $54.63 | $161.35 |
| Average True Range (ATR) | 2.20 | 5.56 |
| MACD | -0.06 | 2.03 |
| Stochastic Oscillator | 24.33 | 62.03 |
Core & Main is a leading specialty distributor with a focus on water, wastewater, storm drainage, and fire protection products. The company provides solutions to municipalities, private water companies, and professional contractors across municipal, nonresidential, and residential end markets. The company's specialty products and services are used in the maintenance, repair, replacement, and construction of water and fire protection infrastructure.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.